Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 2 of 65 · 3073 articles
This study maps gene and microRNA changes linked to ulcerative colitis and tests how deleting STAT6 or treating mice with Corylus avellana extract shifts those molecular signatures. Identifying such molecular players may...
If baseline mucosal gene-expression patterns can identify patients more likely to achieve mucosal healing across drug classes, those patterns could eventually help personalize treatment selection or stratify patients in...
Long-term Phase 3 extension data suggest guselkumab (Tremfya) can sustain clinical and endoscopic remission through three years for some patients with Crohn’s disease.
This preclinical study describes a new cell‑based approach — macrophages engineered to secrete IL‑10 — that reduced inflammation and improved colon outcomes in a mouse colitis model, suggesting a potential avenue for...
This study addresses a common problem in Crohn's patients on infliximab: low drug levels despite IV dosing. It suggests switching to a subcutaneous infliximab formulation can raise and stabilize trough concentrations...
If oral microbes can influence the gut, that could open new ways to monitor or modify disease activity in IBD (for example saliva-based biomarkers or oral-targeted interventions). It also highlights modifiable factors...
A reusable transcriptomic atlas could let researchers compare new IBD biopsy datasets to a common reference, improving cross-study comparisons and helping separate inflammation from persistent disease-state biology that...
The study suggests postbiotics from a gut bacterium can reduce inflammation in a mouse colitis model and identifies a candidate metabolite and signaling pathway that could be targeted in future IBD research.
A simple blood test (CRP) that's already used in IBD care might help predict which Crohn's patients with C. difficile coinfection are more likely to need intestinal surgery, enabling earlier attention or monitoring.
The findings describe a novel cell‑based IL‑10 delivery strategy that reduced experimental colitis and altered gut microbiota—an approach that could inform future IBD therapies research.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Microbiome. The original article is from Stem Cell Research & Therapy.
The trial evaluated an investigational, non-drug vagal nerve stimulation device as a potential therapy for ulcerative colitis in adolescents and young adults, which could expand treatment options beyond conventional...
The study aims to clarify differences in visceral sensitivity and collect multiple biological samples that could help explain why some people with IBD have IBS-like symptoms. Findings could inform better symptom-targeted...
Malnutrition is common in IBD and linked to worse quality of life and outcomes. Validating a standardized GLIM approach could help clinicians identify and treat malnutrition earlier and more consistently in people with...
People with Crohn’s disease who have had, or will have, intestinal surgery may benefit from better tools to predict early complications and endoscopic recurrence. Predictive models could help tailor follow-up and...
This study links brain structure and function differences to clinical measures and neurotransmitter systems in Crohn’s disease, which may help explain cognitive, mood, or quality-of-life effects some people with CD...
People with IBD and coexisting primary sclerosing cholangitis (PSC) are at higher colorectal neoplasia risk and may respond differently to IBD medicines. This meta-analysis compiles available evidence on commonly used...
People with PSC who undergo liver transplant — especially those who have IBD at the time of transplant — remain at elevated risk for colorectal neoplasia, IBD flare or new-onset IBD, and for PSC recurrence. Knowing this...
The work helps explain why people with IBD often have unstable gut microbiomes and limited recovery of beneficial bacteria, linking those patterns to inflammation — which is relevant for efforts to develop...
The study identifies a botanical extract that reduced colitis severity in mice and pinpoints the PI3K/Akt/FOXO3A pathway as a possible mechanism — a potential starting point for new therapeutic research relevant to...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Cureus.
Reports effectiveness and safety of risankizumab specifically in East Asian participants from global phase 2b/3 UC trials, which may inform regional applicability of trial results for people with moderate-to-severe...
Perianal fistulas are a challenging complication of Crohn’s disease with limited effective options; a phase 3 trial reports that guselkumab improved fistula remission rates through 48 weeks, which could offer a new...
IBD is linked to higher skeletal risk; early biochemical changes in Wnt-pathway proteins might identify bone impairment before DXA detects low bone density, potentially helping earlier risk stratification.
If you have moderate-to-severe UC and are treated with adalimumab (or other therapies), this study suggests the rectum may be slower or less likely to reach endoscopic and histologic healing than more proximal colon...
The review evaluates a revised preprint linking GM-CSF, macrophages, and ILC-like cells in Crohn’s disease using human spatial transcriptomics and zebrafish experiments. It highlights limitations that matter because they...
Based on the title and source metadata, this appears to be a market or business news related to Research and clinical trials. The original article is from thepharmaletter.com.
New mouse-model research identifies TIMD4-dependent macrophage pathways that influence monocyte recruitment and colitis severity and tests a TIMD4-derived peptide delivered in nanoparticles that reduced inflammation in...
These patient-derived human tissue models aim to let drug developers test whether a candidate affects disease-relevant biology in human intestinal tissue before moving to clinical trials, which could help reduce failures...
This mid‑stage trial reports strong week‑44 clinical remission and endoscopic response rates for duvakitug, an investigational anti‑TL1A therapy, in both UC and Crohn’s disease — a development that could expand future...
New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect...
Long-term risk of needing another intestinal surgery is a major concern for people with Crohn’s disease. This study suggests laparoscopic resection may be linked to lower long-term reoperation risk compared with open...
Stronger, more sustainable IBD research units can increase patient access to clinical studies, speed up therapeutic and biomarker advances, and make care more research-ready. Patients and clinicians in centers with...
This review connects enteric sensory neuron dysfunction to symptoms common in IBS and IBD (pain, diarrhea, constipation, dysmotility). Understanding IPAN plasticity could point to new treatment targets that act locally...
Postoperative recurrence in Crohn's disease is common and often first detected on endoscopy. If probiotics reduced endoscopic recurrence, it could offer a low-risk, non-pharmacologic strategy to help prevent disease...
Children with Crohn’s disease may have vitamin D deficiency and a theoretical link between vitamin D levels and relapse risk; this trial tested whether adding high‑dose vitamin D3 at diagnosis could lower relapses and...
Distinguishing inflammation from irreversible fibrosis is a common clinical challenge in Crohn’s disease because it affects treatment choices (medical therapy versus surgery). Validated MRI biomarkers could improve...
Cure8 found this source from chicagobusiness.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full...
The study suggests Crohn’s disease is associated with coordinated brain structure and function differences that relate to disease activity and quality of life, pointing to brain–gut links that could inform future...
Staying on an immunomodulator with anti-TNF therapy was linked to greater long-term persistence of the biologic drug, which matters because loss of response to anti-TNF agents is a common problem in Crohn’s disease....
Findings suggest a dietary flavonoid (daidzein) may reduce colitis in mice via microbial activation and host signaling pathways, pointing toward microbiome-informed nutritional approaches for IBD.
Identifying genes and pathways involved in IBD can point to new biological mechanisms, potential biomarkers, and future targets for research that may eventually inform diagnosis or treatment.
The review identifies berberine as a potential adjunct therapy for UC because it may target both gut microbes and epithelial inflammasome-mediated cell death, processes important in disease activity and barrier function.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Inflammopharmacology.
This study reports that an optimized Cycas revoluta leaf extract reduced colon inflammation and markers of oxidative stress in a rat model of ulcerative colitis, suggesting it could be a source of bioactive compounds...
The article offers an Ayurvedic framework for understanding and managing ulcerative colitis that may interest patients seeking complementary approaches and clinicians exploring integrative care. It emphasizes dietary and...
If true, a commonly available dietary change—drinking alkalinised filtered water—might modestly affect inflammatory markers and specific gut bacteria in people with IBD in remission, which could be of interest to...
Patients and clinicians may care because the investigational drug duvakitug reportedly sustained clinical and endoscopic benefits through 44 weeks in both ulcerative colitis and Crohn’s disease, which could represent a...
